Thomas E. Witzig

62.0k total citations · 4 hit papers
778 papers, 34.1k citations indexed

About

Thomas E. Witzig is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Thomas E. Witzig has authored 778 papers receiving a total of 34.1k indexed citations (citations by other indexed papers that have themselves been cited), including 476 papers in Pathology and Forensic Medicine, 295 papers in Genetics and 284 papers in Oncology. Recurrent topics in Thomas E. Witzig's work include Lymphoma Diagnosis and Treatment (456 papers), Chronic Lymphocytic Leukemia Research (263 papers) and Multiple Myeloma Research and Treatments (138 papers). Thomas E. Witzig is often cited by papers focused on Lymphoma Diagnosis and Treatment (456 papers), Chronic Lymphocytic Leukemia Research (263 papers) and Multiple Myeloma Research and Treatments (138 papers). Thomas E. Witzig collaborates with scholars based in United States, Italy and Canada. Thomas E. Witzig's co-authors include Philip R. Greipp, S. Vincent Rajkumar, Stephen M. Ansell, Robert A. Kyle, Martha Q. Lacy, Morie A. Gertz, John A. Lust, Angela Dispenzieri, Rafaël Fonseca and Thomas M. Habermann and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Thomas E. Witzig

744 papers receiving 33.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Review of 1027 Patients With Newly Diagnosed Multiple Myeloma

2003 1.6k citations Robert A. Kyle, Morie A. Gertz et al. profile →
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

2002 841 citations Thomas E. Witzig, Leo I. Gordon et al. Journal of Clinical Oncology profile →
Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis

2004 639 citations Angela Dispenzieri, Morie A. Gertz et al. Journal of Clinical Oncology profile →
Rituximab for IgG4-related disease: a prospective, open-label trial

2015 444 citations Thomas E. Witzig et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Thomas E. Witzig	14.1k	13.5k	11.2k	9.6k	8.6k	778	34.1k
Bruce D. Cheson	17.1k 1.2×	10.6k 0.8×	5.0k 0.4×	6.4k 0.7×	11.0k 1.3×	362	29.9k
L. Jeffrey Medeiros	18.8k 1.3×	14.3k 1.1×	9.2k 0.8×	7.7k 0.8×	10.3k 1.2×	1.3k	40.1k
Wolfgang Hiddemann	9.8k 0.7×	9.3k 0.7×	8.1k 0.7×	11.0k 1.1×	6.9k 0.8×	644	27.2k
Gilles Salles	23.0k 1.6×	17.1k 1.3×	5.1k 0.5×	2.8k 0.3×	10.2k 1.2×	763	34.7k
John F. Seymour	9.8k 0.7×	6.8k 0.5×	5.1k 0.5×	7.9k 0.8×	10.7k 1.2×	561	23.8k
Stephen M. Ansell	13.8k 1.0×	15.0k 1.1×	4.2k 0.4×	2.9k 0.3×	5.6k 0.7×	741	26.6k
Francis J. Giles	6.3k 0.4×	9.3k 0.7×	15.0k 1.3×	20.4k 2.1×	15.8k 1.8×	786	41.9k
Bertrand Coiffier	24.8k 1.8×	16.6k 1.2×	3.7k 0.3×	3.1k 0.3×	9.6k 1.1×	486	33.6k
Jamés O. Armitage	15.9k 1.1×	12.4k 0.9×	2.5k 0.2×	4.3k 0.4×	6.2k 0.7×	487	25.6k
Hartmut Döhner	12.1k 0.9×	7.7k 0.6×	17.5k 1.6×	21.1k 2.2×	19.0k 2.2×	653	44.9k

Countries citing papers authored by Thomas E. Witzig

Since Specialization

Citations

This map shows the geographic impact of Thomas E. Witzig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas E. Witzig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas E. Witzig more than expected).

Fields of papers citing papers by Thomas E. Witzig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas E. Witzig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas E. Witzig. The network helps show where Thomas E. Witzig may publish in the future.

Co-authorship network of co-authors of Thomas E. Witzig

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas E. Witzig. A scholar is included among the top collaborators of Thomas E. Witzig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas E. Witzig. Thomas E. Witzig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Abeykoon, Jithma P., Shuhei Asada, Gui‐Qi Zhu, et al.. (2025). Cyclin D1 overexpression induces replication stress and microhomology-mediated end-joining dependence in mantle cell lymphoma. Journal of Clinical Investigation. 135(17). 1 indexed citations

Kumar, Emil, Koorosh Korfi, Findlay Bewicke‐Copley, et al.. (2024). CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma. British Journal of Haematology. 205(5). 1804–1809. 1 indexed citations

Gile, Jennifer, Matthew J. Maurer, Gordon Ruan, et al.. (2024). Low magnesium levels and prognosis in newly diagnosed diffuse large B-cell lymphoma. The Oncologist. 29(12). e1779–e1782.

Wang, Jacqueline, Jihao Zhou, Han W. Tun, et al.. (2024). Association of Sex, Race and Ethnicity with Clinical Characteristics and Survival Outcomes of Mantle Cell Lymphoma: A National Cancer Database Study. Blood. 144(Supplement 1). 1637–1637.

Boddicker, Nicholas, Melissa C. Larson, Alessia Castellino, et al.. (2021). Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era. American Journal of Hematology. 96(8). 979–988. 10 indexed citations

Khurana, Arushi, Raphael Mwangi, Grzegorz S. Nowakowski, et al.. (2021). Impact of Organ Function–Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?. Journal of Clinical Oncology. 39(15). 1641–1649. 21 indexed citations

Evens, Andrew M., Fangxin Hong, Thomas M. Habermann, et al.. (2020). A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. Clinical Cancer Research. 26(17). 4468–4477. 16 indexed citations

Buadi, Francis K., Martha Q. Lacy, Gabriela Pérez, et al.. (2020). Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients with Multiple Myeloma with Extramedullary Disease or Plasma Cell Leukemia. Blood. 136(Supplement 1). 34–35. 1 indexed citations

Wang, Yucai, Umar Farooq, Brian K. Link, et al.. (2018). Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era. Blood. 132(Supplement 1). 454–454. 1 indexed citations

10.

Braggio, Esteban, Scott Van Wier, Juhi Ojha, et al.. (2015). Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas. Clinical Cancer Research. 21(17). 3986–3994. 150 indexed citations

11.

Witzig, Thomas E., Craig B. Reeder, Jing Han, et al.. (2015). The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood. 126(3). 328–335. 83 indexed citations

12.

Nowakowski, Grzegorz S., Betsy LaPlant, William R. Macon, et al.. (2014). Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non–Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study. Journal of Clinical Oncology. 33(3). 251–257. 268 indexed citations

13.

Kapoor, Prashant, Shaji Kumar, Angela Dispenzieri, et al.. (2013). Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma. Journal of Clinical Oncology. 31(36). 4529–4535. 120 indexed citations

14.

Chen, Christopher Y., Julien S. Senac, Eric A. Weaver, et al.. (2011). Species D Adenoviruses as Oncolytics against B-cell Cancers. Clinical Cancer Research. 17(21). 6712–6722. 37 indexed citations

15.

Ghobrial, Irene M., Morie A. Gertz, Betsy LaPlant, et al.. (2010). Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia. Journal of Clinical Oncology. 28(8). 1408–1414. 102 indexed citations

16.

Kelly, Jennifer L., Anne J. Novak, Zachary S. Fredericksen, et al.. (2010). Germline Variation in Apoptosis Pathway Genes and Risk of Non–Hodgkin's Lymphoma. Cancer Epidemiology Biomarkers & Prevention. 19(11). 2847–2858. 34 indexed citations

17.

Shanafelt, Tait D., Matthew T. Drake, Matthew J. Maurer, et al.. (2010). Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood. 117(5). 1492–1498. 104 indexed citations

18.

Yang, Zhi‐Zhang, Anne J. Novak, Steven C. Ziesmer, Thomas E. Witzig, & Stephen M. Ansell. (2009). Malignant B Cells Skew the Balance of Regulatory T Cells and TH17 Cells in B-Cell Non-Hodgkin's Lymphoma. Cancer Research. 69(13). 5522–5530. 131 indexed citations

19.

Nowakowski, Grzegorz S., Matthew J. Maurer, Thomas M. Habermann, et al.. (2009). Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era. Journal of Clinical Oncology. 28(3). 412–417. 45 indexed citations

20.

Czuczman, Myron S., Christos Emmanouilides, Mohamed Darif, et al.. (2007). Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan Radioimmunotherapy. Journal of Clinical Oncology. 25(27). 4285–4292. 93 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact